Introducing Bio3: the next evolution of biotech
Biotech has always evolved in waves: from the pharma giants of the 20th century (Bio1), to the venture-backed biotech startups of the 1980s (Bio2). Each era solved inefficiencies while creating new ones.
Today, a new epoch is emerging: Bio3. Powered by DeFi, DeSci, and AI, Bio3 combines the scale of pharma, the focus of biotech, and the liquidity of Web3 into accessible, networked and curative ecosystems.
Bio3 will lower the costs and barriers of healthcare development while valuing patients as partners in progress, not just consumers of it.
Meridian Science, as the first Bio3-native pioneer, is the tailwind biotech needs.
We fund and execute on the world's most promising life science breakthroughs globally
Researchers
Access to a global network of academic partners
R&D Projects
Creation of tokenized R&D funding and execution verticals
Making a business model out of the Valley of Death
PRE-SEED
- Direct funding of $250k–$500k from Meridian
- IP tokenization
- Activate community interest
- Token sales $0.5 - $3.5m
- Milestone-based follow-on funding for continued development
- Community building
- Funding: $5M–$30M
- Life Science Investors
- Biotech Venture Creation
- Community Transition
“We incubate projects from inception, de-risk them through milestone-driven funding, and execute with on-demand capital, talent, and liquidity.”